Kikuchi-Fujimoto disease (KFD) is a benign, self-limited lymphadenitis that predominantly affects young women. A positive antinuclear antibody (ANA) test in patients with KFD has long been a source of clinical uncertainty and patient anxiety, raising concerns about future progression to systemic lupus erythematosus (SLE) or other rheumatic diseases. Now, a new study from Beijing Friendship Hospital, Capital Medical University, provides a reassuring answer: ANA positivity does not predict progression to rheumatic disease.
The findings, published in the journal Rheumatology & Autoimmunity, offer clinicians and patients much-needed clarity. Among 140 patients with biopsy-confirmed KFD followed for up to 10 years, none developed SLE, and the relapse rate was low—regardless of ANA status.
“For years, we have faced a critical unanswered question: Does a positive ANA test in a patient with KFD signal an impending autoimmune disease?” said Dr. Zhang , First author of the study. “Our findings are reassuring. The vast majority of these patients recover completely and do not require aggressive treatment or undue worry.”
Background: An Unanswered Clinical Question
KFD, also known as histiocytic necrotizing lymphadenitis, is a benign, self-limited condition first described in 1972. It predominantly affects young Asian women, presenting with fever and cervical lymphadenopathy. While KFD is known to be associated with autoimmune conditions—particularly SLE—the clinical significance of frequently detected ANAs has remained unclear, creating substantial anxiety for patients and clinicians alike.
Key Findings: Addressing the Core Question with Robust Data
The retrospective cohort study included 140 patients with biopsy-confirmed KFD treated at Beijing Friendship Hospital between 2015 and 2025, representing one of the largest and longest-followed cohorts to date.
The study's most important findings include:
Low concurrent rheumatic disease rate: Only 10 patients (7.1%) had concurrent rheumatic diseases at initial presentation.
High ANA positivity: Among the 130 patients without rheumatic diseases at baseline, the ANA positivity rate was 60.0% (78/130). Of these, 11.5% (9/78) also carried other autoantibodies, including anti-Sm, anti-SSA, and anti-ribosomal P protein.
Minimal progression risk: With a median follow-up of 39 months (range: 1–120 months), 107 patients (82.3%) completed follow-up. Most importantly, no patient developed SLE during the entire observation period. Only one ANA-positive patient developed rheumatoid arthritis, and one developed ankylosing spondylitis.
Low relapse rate: Only 6 relapses (5.6%) occurred, with no significant difference between ANA-positive and ANA-negative groups (5.9% vs. 5.1%, P =1.000). Kaplan-Meier analysis confirmed no significant difference in relapse-free survival between the two groups ( P =0.652).
Transient ANA positivity: Among the 15 patients who underwent repeat ANA testing, 11 (73.3%) seroconverted to negative, suggesting that ANA positivity in KFD is usually a transient phenomenon.
Clinical Implications: Reassurance for Patients and Clinicians
The study's message is clear and actionable: ANA positivity is common in KFD, but the risk of progression to rheumatic disease is low. The vast majority of patients have favorable outcomes, and the short-term risk of developing connective tissue diseases is minimal. However, given the inherent limitations of a retrospective study and the small number of patients who underwent repeat ANA testing, the authors recommend continued long-term follow-up for patients with autoantibodies.
“These findings should change how we counsel patients,” said Dr. Liu , corresponding author of the study. “A positive ANA test in KFD should not be viewed as a harbinger of lupus. Patients can be reassured that their prognosis is excellent.”
Conclusion and Future Directions
This study provides important evidence that ANA positivity in KFD—even when accompanied by other autoantibodies—does not predict progression to SLE or other connective tissue diseases. Most patients recover completely and do not require excessive treatment or undue anxiety.
Further research is needed to identify patients at genuine risk of progression to CTDs and to optimize long-term follow-up strategies.
Rheumatology & Autoimmunity
Observational study
People
Clinical significance of antinuclear antibodies in patients with Kikuchi-Fujimoto disease: a retrospective cohort study
2-Jul-2026
Yanying Liu is a member of the Rheumatology & Autoimmunity editorial board and is not involved in the peer-review process of this article. The remaining authors declare no conflicts of interest.